Oliver Kubli

Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG.

Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.

Zürcher Kantonalbank (Investment Management) (ZKB-IM) is the investment management division of Zürcher Kantonalbank, a Swiss full-service bank headquartered in Zurich. Founded in 1870, ZKB-IM performs the bank's investment activities, including financial advisory services, research, trading, and asset management. The asset management division provides investment solutions for institutional, corporate and private clients, managing discretionary mandates and the ZKB range of mutual funds. Their mission includes fostering economic growth in the Canton of Zurich.

Zürcher Kantonalbank engages in the provision of universal banking services. It offers its services through the following divisions: Private Banking, International Banking and Asset Management. The Private Banking division offers private advisory, asset management, fiduciary and other services. The International Banking division provides international payments and trade finance services. The Asset Management division includes segregated, balanced and overlay mandates. It also offers strategy advice and portfolio analysis services. The company was founded on February 15, 1870 and is headquartered in Zürich, Switzerland.

Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland.

Adamant Biomedical Investments AG (Adamant) is the subsidiary of Bellevue Group AG (SW: BBN) in Switzerland. The firm was established in 2000 as a joint venture between Swiss Life Asset Management and three partners, formerly with the Bellevue Group (which comprises BB Biotech and BB Medtech). The firm's name derives from the Greek word for 'uncut diamond' and refers to their philosophy of uncovering hidden value. Located in Zurich, Adamant is a biomedical sector specialist. The firm manages sector-specific portfolios domiciled in Luxembourg. Their clients are institutions.